KRAS mutations: analytical considerations.
作者： Marta Herreros-Villanueva , Chih-Chieh Chen , Shyng-Shiou F Yuan , Ta-Chih Liu , Tze-Kiong Er
DOI: 10.1016/J.CCA.2014.01.049
关键词:
摘要: Abstract Colorectal cancer (CRC) is the third most common and second cause of death globally. Significant improvements in survival have been made patients with metastasis by new therapies. For example, Cetuximab Panitumumab are monoclonal antibodies that inhibit epidermal growth receptor (EGFR). KRAS mutations codon 12 13 recognized biomarkers analyzed clinics before administration anti-EGFR therapy. Genetic analyses revealed predict a lack response to metastatic CRC (mCRC). Notably, it estimated 35–45% harbor mutations. Therefore, mutation testing should be performed all individuals advanced order identify who will not respond EGFR antibody inhibitors. New techniques for arisen rapidly, each technique has advantages disadvantages. Herein, we review latest published literature specific techniques. Since reliability feasibility important issues clinical analyses. this also summarizes effectiveness limitations numerous
sci-hub.se 参考文章(118)
Tien-Jye Chang, Kun-Tu Yeh, Tze-Kiong Er, Jan-Gowth Chang, Ya-Sian Chang, Comparison of Two Different Screening Methods for the KRAS Mutation in Colorectal Cancer Clinical Laboratory. ,vol. 56, pp. 175- ,(2010)
Jianfei Wang, Hongying Yang, Yinchen Shen, Shuai Wang, Dongmei Lin, Li Ma, Xiaohong Han, Yuankai Shi, Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Criminal Behaviour and Mental Health. ,vol. 13, pp. 89- 97 ,(2013) , 10.3233/CBM-130334
Salih Ibrahem, Rashmi Seth, Brendan O’Sullivan, Wakkas Fadhil, Philippe Taniere, Mohammad Ilyas, Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection. International Journal of Experimental Pathology. ,vol. 91, pp. 500- 505 ,(2010) , 10.1111/J.1365-2613.2010.00733.X
Bárbara Angulo, Elena García-García, Rebeca Martínez, Ana Suárez-Gauthier, Esther Conde, Manuel Hidalgo, Fernando López-Ríos, A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations The Journal of Molecular Diagnostics. ,vol. 12, pp. 292- 299 ,(2010) , 10.2353/JMOLDX.2010.090139
Wakkas Fadhil, Salih Ibrahem, Rashmi Seth, Ghada AbuAli, Krishna Ragunath, Philip Kaye, Mohammad Ilyas, The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer Histopathology. ,vol. 61, pp. 1117- 1124 ,(2012) , 10.1111/J.1365-2559.2012.04321.X
Yasuhide Yamada, Yoshitaka Honma, Kohei Akiyoshi, Yasuhiro Shimada, Hirokazu Taniguchi, Satoru Iwasa, Ken Kato, Tetsuya Hamaguchi, Koh Furuta, KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing. Anticancer Research. ,vol. 33, pp. 2129- 2134 ,(2013)
Serena Bonin, Falk Hlubek, Jean Benhattar, Carsten Denkert, Manfred Dietel, Pedro L. Fernandez, Gerald Höfler, Hannelore Kothmaier, Bozo Kruslin, Chiara Maria Mazzanti, Aurel Perren, Helmuth Popper, Aldo Scarpa, Paula Soares, Giorgio Stanta, Patricia J. T. A. Groenen, Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Archiv. ,vol. 457, pp. 309- 317 ,(2010) , 10.1007/S00428-010-0917-5
Marta Herreros-Villanueva, Gaurav Aggarwal, KRAS assay selection: sensitivity and accuracy in clinical application. Molecular Biology Reports. ,vol. 39, pp. 2467- 2470 ,(2012) , 10.1007/S11033-011-0997-6
Peter H. Seeburg, Wendy W. Colby, Daniel J. Capon, David V. Goeddel, Arthur D. Levinson, Biological properties of human c-Ha-ras1 genes mutated at codon 12 Nature. ,vol. 312, pp. 71- 75 ,(1984) , 10.1038/312071A0
S Ogino, P Lochhead, E Giovannucci, J A Meyerhardt, C S Fuchs, A T Chan, Discovery of Colorectal Cancer PIK3CA Mutation as Potential Predictive Biomarker: Power and Promise of Molecular Pathological Epidemiology Oncogene. ,vol. 33, pp. 2949- 2955 ,(2014) , 10.1038/ONC.2013.244